AgX100® I125 Implants: Loose Seeds and Cartridge loaded - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant - ARTG 472645
Access comprehensive regulatory information for AgX100® I125 Implants: Loose Seeds and Cartridge loaded - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is registered under ARTG number 472645 and sponsored by RQSolutions Medical Devices Distribution Support, manufactured by Theragenics Corporation in United States of America. The device registration started on December 11, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.
AgX100® seeds are indicated for the permanent interstitial treatment of localized prostate cancer. The seeds may be used as a primary monotherapy (single treatment) or in combination with other treatment modalities such as external beam radiation therapy and/or androgen deprivation therapy.